Linear peptide compound and application thereof

Abstract

Relates to a straight-chain peptide compound and an application thereof, and particularly provides a straight-chain peptide compound which is shown as a formula O and has a novel structure and an effect equivalent to or even better than that of GHK tripeptide, and an application of the straight-chain peptide compound in a dermatological or cosmetic composition for stimulating hair growth or resisting skin aging. R1-(AA1) n1-(AA2) n2-(L1) n3-(AA3) n4-AAa-AAb-AAc-(L2) n5-(AA4) n6-(AA5) n7-(AAa-AAb-AAc) m-R2 Formula O

Description

Linear peptide compounds and their applications

[0001] Citation of Related Applications

[0002] This application claims priority to Chinese patent application CN202311272706.9 filed on September 27, 2023 and Chinese patent application CN202411324581.4 filed on September 20, 2024, the contents of which are incorporated by reference into this application in their entirety and for all purposes. Technical Field

[0003] The present invention relates to the field of biomedicine or cosmetic products, and in particular to a linear peptide compound and application thereof. Background Art

[0004] GHK is a tripeptide molecule, also known as tripeptide or tripeptide-1. Its sequence is glycyl-histidyl-lysine, and it's a product of collagen hydrolysis. It's naturally present in human blood, saliva, and urine. GHK is known for its ability to boost the production of type I collagen fragments. Its mechanism of action can be simply understood as when collagen naturally breaks down in the skin, the resulting peptide fragments signal the skin to get to work and produce some beautiful new collagen.

[0005] GHK has a high affinity for divalent copper ions and can spontaneously combine with them to form a complex GHK-Cu, which is also called blue copper peptide because its aqueous solution is blue. It is the main form in which GHK exerts its effects in the body. Its functions mainly include: (1) chemotaxis of repair cells, such as macrophages, mast cells, and capillary cells; (2) anti-inflammatory effects (inhibiting free radicals, thromboxane formation, transforming growth factor β-1, tumor necrosis factor α and protein glycation, while increasing superoxide dismutase, dilating blood vessels, blocking ultraviolet damage to skin keratinocytes and improving the recovery of fibroblasts after X-ray treatment); (3) increasing the protein synthesis of collagen, elastin, hyaluronic acid, metalloproteinases, antiproteinases, vascular endothelial growth factor, fibroblast growth factor 2, nerve growth factor, neutrophil 3 and 4, and erythropoietin; (4) increasing the proliferation of fibroblasts and keratinocytes; nerve growth, angiogenesis, and hair follicle size. Controlled studies on aging skin have shown that GHK-Cu can tighten the skin, improve elasticity and firmness, reduce fine lines, wrinkles, photodamage and hyperpigmentation, and promote hair growth and improve the success rate of hair transplantation.

[0006] Summary of the Invention

[0007] The present invention provides a linear peptide compound with novel structure and efficacy comparable to or even better than that of GHK tripeptide, and its use in dermatological or cosmetic compositions for stimulating hair growth or anti-aging of skin.

[0008] To this end, in the first aspect of the present invention, the present invention provides a linear peptide compound represented by formula O or a stereoisomer thereof,

[0009] R 1 -(AA 1 ) n1 -(AA 2 ) n2 -(L 1 ) n3 -(AA 3 ) n4 -AA a -AA b -AA c -(L 2 ) n5 -(AA 4 ) n6 -(AA 5 ) n7 -(AA a -AA b -AA c ) m -R 2

[0010] Formula O

[0011] in:

[0012] n1, n2, n3, n4, n5, n6, and n7 are each independently selected from 0 and 1; m is selected from 0 and 1; and the following two conditions are satisfied:

[0013] 1) When n1 and n7 are both 0, n3 and n5 are not both 0;

[0014] 2) When n3 and n5 are both 0, n1 and n7 are not both 0;

[0015] AA a An amino acid residue selected from the group consisting of GLY, LYS, DLYS, LYO, LHY, LHI, LPY;

[0016] Preferably, AA a An amino acid residue selected from the group consisting of GLY, LYS, DLYS, LYO, LHY;

[0017] More preferably, AA a are the following amino acid residues: GLY, LYS;

[0018] AA bselected from the following amino acid residues: HIS, DHIS;

[0019] Preferably, AA b are the following amino acid residues: HIS;

[0020] AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY, GLY;

[0021] Preferably, AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, GLY;

[0022] More preferably, AA c An amino acid residue selected from the group consisting of LYS, LYO, LHY, GLY;

[0023] Most preferably, AA c are the following amino acid residues: LYS, GLY;

[0024] Among them, AA a When the amino acid residues are: GLY, AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY, and AA a When selected from the following amino acid residues: LYS, DLYS, LYO, LHY, LHI, LPY, AA c is the following amino acid residue: GLY;

[0025] Preferably, AA a -AA b -AA c selected as a whole from the following peptide residues: GLY HIS LYS, LYS HIS GLY, GLY DHISDLYS, GLY HIS LYO, GLY HIS LHY, GLY HIS LHI, GLY HIS LPY;

[0026] AA 1 Selected from the following amino acid residues: AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, D-M3L;

[0027] Preferably, AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0028] More preferably, AA 1 selected from the following amino acid residues: 4PH, ZCL, A30;

[0029] Most preferably, AA1 are the following amino acid residues: M3L;

[0030] AA 2 Selected from M3L, 2MR, ALA, GLY;

[0031] Preferably, AA 2 selected from the following amino acid residues: M3L, 2MR;

[0032] More preferably, AA 2 are the following amino acid residues: M3L;

[0033] Or preferably, AA 2 Selected from ALA, GLY;

[0034] AA 3 are the following amino acid residues: M3L;

[0035] AA 4 Selected from the following amino acid residues: ALA, GLY, PRO;

[0036] Preferably, AA 4 selected from the following amino acid residues: ALA, GLY;

[0037] AA 5 Selected from the following amino acid residues: M3L, 4PH, ZCL, A30, DOQ, EXL, 0UO, D-4PH, D-ZCL, D-A30;

[0038] Preferably, AA 5 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0039] More preferably, AA 5 Selected from the following amino acid residues: 4PH, M3L.

[0040] R 1 Selected from ACE, PAL, BIO, PEG, VIC;

[0041] Preferably, R 1 Selected from ACE, PAL, BIO;

[0042] More preferably, R 1 For ACE;

[0043] R 2 Selected from NME, -OH, -NH2;

[0044] Preferably, R 2 For NME;

[0045] L 1Selected from P01, P02, P03, P04, P05, P06, P07, P08, P09, P10, P11, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25, P26, P27, P28, P29, P30;

[0046] Preferably, L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0047] More preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0048] Most preferably, L 1 Selected from P23, P21, P06, P20, P25;

[0049] L 2 Selected from P01, P02, P03, P04, P05, P06, P07, P08, P09, P10, P11, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25, P26, P27, P28, P29, P30;

[0050] Preferably, L 2 Selected from P05, P06, P07, P08, P19, P20, P21, P22, P23, P24, P25, P29;

[0051] More preferably, L 2 Selected from P05, P06, P07, P08, P19, P20, P21, P22, P23, P24, P25;

[0052] Wherein, in the linear peptide compound represented by Formula O, from left to right is N-terminus to C-terminus;

[0053] Among them, the meanings of P01, P02, P03, P04, P05, P06, P07, P08, P09, P10, P11, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25, P26, P27, P28, P29, P30, ACE, PAL, BIO, PEG, VIC, NME, GLY, HIS, DHIS, LYS, DLYS, LYO, LHY, LHI, LPY, AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, DOQ, EXL, 0UO, D-4PH, D-ZCL, D-A30, D-M3L, ALA, and PRO are as shown in Table E.

[0054] In some embodiments, the linear peptide compound has a structure shown in Formula I,

[0055] R 1 -AA a -AA b -AA c -L 2 -AA a -AA b -AA c -R 2

[0056] Formula I

[0057] in:

[0058] AA a is the following amino acid residue: GLY;

[0059] AA b selected from the following amino acid residues: HIS, DHIS;

[0060] Preferably, AA b are the following amino acid residues: HIS;

[0061] AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0062] Preferably, AA c are the following amino acid residues: LYS;

[0063] Preferably, AA a -AA b -AA c As a whole, the following peptide residues: GLY HIS LYS;

[0064] R 1Selected from ACE, PAL, BIO;

[0065] Preferably, R 1 For ACE;

[0066] R 2 Selected from NME, -OH, -NH2;

[0067] Preferably, R 2 For NME;

[0068] L 2 Selected from P01, P02, P03, P04, P05, P06, P07, P08, P09, P10, P11, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25, P26, P27, P28, P29, P30;

[0069] Preferably, L 2 Selected from P05, P06, P07, P08, P19, P20, P21, P22, P23, P24, P25, P29;

[0070] More preferably, L 2 Selected from P05, P06, P07, P08, P19, P20, P21, P22, P23, P24, P25.

[0071] In some embodiments, the linear peptide compound has a structure shown in Formula II,

[0072] R 1 -(AA 1 ) n1 -(AA 2 ) n2 -L 1 -(AA 3 ) n4 -AA a -AA b -AA c -(AA 4 ) n6 -(AA 5 ) n7 -R 2

[0073] Formula II

[0074] in:

[0075] n1, n2, n4, n6, n7 are each independently selected from 0, 1;

[0076] Preferably, n1 is selected from 0 and 1, and n2, n4, n6, and n7 are all 0;

[0077] Or preferably, n1, n2, n4, n6, and n7 are all 0;

[0078] AA a An amino acid residue selected from the group consisting of GLY, LYS, DLYS, LYO, LHY;

[0079] Preferably, AA a selected from the following amino acid residues: GLY, LYS;

[0080] AA b selected from the following amino acid residues: HIS, DHIS;

[0081] Preferably, AA b are the following amino acid residues: HIS;

[0082] AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, GLY;

[0083] Preferably, AA c An amino acid residue selected from the group consisting of LYS, LYO, LHY, GLY;

[0084] Preferably, AA c selected from the following amino acid residues: LYS, GLY;

[0085] Among them, AA a When the amino acid residues are: GLY, AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, and AA a When selected from the following amino acid residues: LYS, DLYS, LYO, LHY, AA c is the following amino acid residue: GLY;

[0086] Preferably, AA a -AA b -AA c As a whole, selected from the following peptide residues: GLY HIS LYS, LYS HIS GLY, GLY DHISDLYS, GLY HIS LYO, GLY HIS LHY;

[0087] AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0088] Preferably, AA 1 are the following amino acid residues: M3L;

[0089] AA 2 are the following amino acid residues: M3L;

[0090] AA 3 are the following amino acid residues: M3L;

[0091] AA 4 selected from the following amino acid residues: GLY, ALA;

[0092] AA 5 are the following amino acid residues: 4PH;

[0093] R 1 Selected from ACE, PAL, BIO;

[0094] Preferably, R 1 For ACE;

[0095] R 2 Selected from NME, -OH, -NH2;

[0096] Preferably, R 2 For NME;

[0097] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0098] Preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0099] More preferably, L 1 Selected from P23, P21, P06, P20, P25.

[0100] In some embodiments, the linear peptide compound has the structure shown in Formula II-1,

[0101] R 1 -(AA 1 ) n1 -(AA 2 ) n2 -L 1 -(AA 3 ) n4 -AA a1 -AA b1 -AA c1 -(AA 4 ) n6 -(AA 5 ) n7-R 2

[0102] Formula II-1

[0103] in:

[0104] n1, n2, n4, n6, n7 are each independently selected from 0, 1;

[0105] Preferably, n1 is selected from 0 and 1, and n2, n4, n6, and n7 are all 0;

[0106] AA a1 is the following amino acid residue: GLY;

[0107] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0108] Preferably, AA b1 are the following amino acid residues: HIS;

[0109] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0110] Preferably, AA c1 are the following amino acid residues: LYS, LYO, LHY;

[0111] Preferably, AA c1 are the following amino acid residues: LYS;

[0112] Preferably, AA a1 -AA b1 -AA c1 As a whole, selected from the following peptide residues: GLY HIS LYS, GLY DHISDLYS, GLY HIS LYO, GLY HIS LHY;

[0113] AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0114] Preferably, AA 1 are the following amino acid residues: M3L;

[0115] AA 2 are the following amino acid residues: M3L;

[0116] AA 3 are the following amino acid residues: M3L;

[0117] AA 4 selected from the following amino acid residues: GLY, ALA;

[0118] AA 5 are the following amino acid residues: 4PH;

[0119] R 1 Selected from ACE, PAL, BIO;

[0120] Preferably, R 1 For ACE;

[0121] R 2 Selected from NME, -OH, -NH2;

[0122] Preferably, R 2 For NME;

[0123] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0124] Preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0125] More preferably, L 1 Selected from P23, P21, P06, P20, P25.

[0126] In some embodiments, the linear peptide compound has a structure shown in Formula II-1-1,

[0127] R 1 -L 1 -AA a1 -AA b1 -AA c1 -R 2

[0128] Formula II-1-1

[0129] in:

[0130] AA a1 is the following amino acid residue: GLY;

[0131] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0132] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0133] Preferably, AA a1 -AA b1 -AAc1 As a whole, selected from the following peptide residues: GLY HIS LYS, GLY DHISDLYS, GLY HIS LYO, GLY HIS LHY;

[0134] R 1 Selected from ACE, PAL, BIO;

[0135] R 2 Selected from NME, -OH, -NH2;

[0136] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0137] Preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0138] More preferably, L 1 Selected from P23, P21, P06, P20, P25, P29;

[0139] Most preferably, L 1 Selected from P21, P06, and P25.

[0140] In some embodiments, the linear peptide compound has a structure shown in Formula II-1-2,

[0141] R 1 -AA 1 -L 1 -AA a1 -AA b1 -AA c1 -R 2

[0142] Formula II-1-2

[0143] in:

[0144] AA a1 is the following amino acid residue: GLY;

[0145] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0146] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0147] Preferably, AA a1-AA b1 -AA c1 As a whole, selected from the following peptide residues: GLY HIS LYS, GLY DHISDLYS, GLY HIS LYO, GLY HIS LHY;

[0148] AA 1 selected from the following amino acid residues: M3L, 4PH;

[0149] R 1 Selected from ACE, PAL, BIO;

[0150] R 2 Selected from NME, -OH, -NH2;

[0151] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0152] Preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0153] More preferably, L 1 Selected from P23, P21, and P06.

[0154] In some embodiments, the linear peptide compound has a structure shown in Formula II-1-3,

[0155] R 1 -L 1 -AA 3 -AA a1 -AA b1 -AA c1 -R 2

[0156] Formula II-1-3

[0157] in:

[0158] AA a1 is the following amino acid residue: GLY;

[0159] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0160] Preferably, AA b1 are the following amino acid residues: HIS;

[0161] AA c1An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0162] Preferably, AA c1 are the following amino acid residues: LYS;

[0163] Preferably, AA a1 -AA b1 -AA c1 As a whole, the following peptide residues: GLY HIS LYS;

[0164] AA 3 are the following amino acid residues: M3L;

[0165] R 1 Selected from ACE, PAL, BIO;

[0166] R 2 Selected from NME, -OH, -NH2;

[0167] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29;

[0168] Preferably, L 1 Selected from P23, P21, P06, P20, P25, P29.

[0169] In some embodiments, the linear peptide compound has a structure shown in Formula II-1-4,

[0170] R 1 -AA 1 -AA 2 -L 1 -AA a1 -AA b1 -AA c1 -R 2

[0171] Formula II-1-4

[0172] in:

[0173] AA a1 is the following amino acid residue: GLY;

[0174] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0175] Preferably, AA b1 are the following amino acid residues: HIS;

[0176] AA c1An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0177] Preferably, AA c1 are the following amino acid residues: LYS;

[0178] Preferably, AA a1 -AA b1 -AA c1 As a whole, the following peptide residues: GLY HIS LYS;

[0179] AA 1 selected from the following amino acid residues: 4PH, ZCL, A30;

[0180] AA 2 are the following amino acid residues: M3L;

[0181] R 1 Selected from ACE, PAL, BIO;

[0182] Preferably, R 1 For ACE;

[0183] R 2 Selected from NME, -OH, -NH2;

[0184] Preferably, R 2 For NME;

[0185] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20;

[0186] Preferably, L 1 Selected from P23, P21, P06, P20.

[0187] In some embodiments, the linear peptide compound has a structure shown in Formula II-1-5,

[0188] R 1 -L 1 -AA a1 -AA b1 -AA c1 -AA 5 -R 2

[0189] Formula II-1-5

[0190] in:

[0191] AA a1 is the following amino acid residue: GLY;

[0192] AA b1selected from the following amino acid residues: HIS, DHIS;

[0193] Preferably, AA b1 are the following amino acid residues: HIS;

[0194] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0195] Preferably, AA c1 are the following amino acid residues: LYS;

[0196] Preferably, AA a1 -AA b1 -AA c1 As a whole, the following peptide residues: GLY HIS LYS;

[0197] AA 5 are the following amino acid residues: 4PH;

[0198] R 1 Selected from ACE, PAL, BIO;

[0199] Preferably, R 1 For ACE;

[0200] R 2 Selected from NME, -OH, -NH2;

[0201] Preferably, R 2 For NME;

[0202] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20;

[0203] Preferably, L 1 Selected from P23, P21, P06, P20.

[0204] In some embodiments, the linear peptide compound has a structure shown in Formula II-1-6,

[0205] R 1 -L 1 -AA a1 -AA b1 -AA c1 -AA 4 -AA 5 -R 2

[0206] Formula II-1-6

[0207] in:

[0208] AA a1 is the following amino acid residue: GLY;

[0209] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0210] Preferably, AA b1 are the following amino acid residues: HIS;

[0211] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0212] Preferably, AA c1 are the following amino acid residues: LYS;

[0213] Preferably, AA a1 -AA b1 -AA c1 As a whole, the following peptide residues: GLY HIS LYS;

[0214] AA 4 selected from the following amino acid residues: GLY, ALA;

[0215] AA 5 are the following amino acid residues: 4PH;

[0216] R 1 Selected from ACE, PAL, BIO;

[0217] Preferably, R 1 For ACE;

[0218] R 2 Selected from NME, -OH, -NH2;

[0219] Preferably, R 2 For NME;

[0220] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20;

[0221] Preferably, L 1 Selected from P23, P21, P06, P20.

[0222] In some embodiments, the linear peptide compound has a structure shown in Formula II-1-7,

[0223] R 1 -AA 1 -L 1 -AA a1 -AAb1 -AA c1 -AA 4 -AA 5 -R 2

[0224] Formula II-1-7

[0225] in:

[0226] AA a1 is the following amino acid residue: GLY;

[0227] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0228] Preferably, AA b1 are the following amino acid residues: HIS;

[0229] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0230] Preferably, AA c1 are the following amino acid residues: LYS;

[0231] Preferably, AA a1 -AA b1 -AA c1 As a whole, the following peptide residues: GLY HIS LYS;

[0232] AA 1 are the following amino acid residues: M3L;

[0233] AA 4 selected from the following amino acid residues: GLY, ALA;

[0234] Preferably, AA 4 are the following amino acid residues: ALA;

[0235] AA 5 are the following amino acid residues: 4PH;

[0236] R 1 Selected from ACE, PAL, BIO;

[0237] Preferably, R 1 For ACE;

[0238] R 2 Selected from NME, -OH, -NH2;

[0239] Preferably, R 2 For NME;

[0240] L1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20;

[0241] Preferably, L 1 Selected from P23, P21, P06, P20.

[0242] In some embodiments, the linear peptide compound has a structure shown in Formula II-2,

[0243] R 1 -(AA 1 ) n1 -L 1 -AA a2 -AA b2 -AA c2 -R 2

[0244] Formula II-2

[0245] in:

[0246] n1 is selected from 0 and 1;

[0247] Preferably, n1 is 0;

[0248] AA a2 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0249] Preferably, AA a2 are the following amino acid residues: LYS;

[0250] AA b2 selected from the following amino acid residues: HIS, DHIS;

[0251] Preferably, AA b2 are the following amino acid residues: HIS;

[0252] AA c2 is the following amino acid residue: GLY;

[0253] Preferably, AA a2 -AA b2 -AA c2 As a whole, the following peptide residues: LYS HIS GLY;

[0254] AA 1 are the following amino acid residues: M3L;

[0255] R 1 Selected from ACE, PAL, BIO;

[0256] R 2Selected from NME, -OH, -NH2;

[0257] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29;

[0258] Preferably, L 1 Selected from P23, P21, P06, P20, P25, P29;

[0259] More preferably, L 1 Selected from P23, P21, P06, P20, P25.

[0260] In some embodiments, the linear peptide compound has the structure shown in Formula II-2-1,

[0261] R 1 -L 1 -AA a2 -AA b2 -AA c2 -R 2

[0262] Formula II-2-1

[0263] in:

[0264] AA a2 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0265] Preferably, AA a2 are the following amino acid residues: LYS;

[0266] AA b2 selected from the following amino acid residues: HIS, DHIS;

[0267] Preferably, AA b2 are the following amino acid residues: HIS;

[0268] AA c2 is the following amino acid residue: GLY;

[0269] Preferably, AA a2 -AA b2 -AA c2 As a whole, the following peptide residues: LYS HIS GLY;

[0270] R 1 Selected from ACE, PAL, BIO;

[0271] R 2 Selected from NME, -OH, -NH2;

[0272] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29-;

[0273] Preferably, L 1 Selected from P23, P21, P06, P20, P25, P29;

[0274] More preferably, L 1 Selected from P23, P21, P06, P20, P25.

[0275] In some embodiments, the linear peptide compound has the structure shown in Formula II-2-2,

[0276] R 1 -AA 1 -L 1 -AA a2 -AA b2 -AA c2 -R 2

[0277] Formula II-2-2

[0278] in:

[0279] AA a2 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0280] Preferably, AA a2 are the following amino acid residues: LYS;

[0281] AA b2 selected from the following amino acid residues: HIS, DHIS;

[0282] Preferably, AA b2 are the following amino acid residues: HIS;

[0283] AA c2 is the following amino acid residue: GLY;

[0284] Preferably, AA a2 -AA b2 -AA c2 As a whole, the following peptide residues: LYS HIS GLY;

[0285] AA 1 are the following amino acid residues: M3L;

[0286] R 1 Selected from ACE, PAL, BIO;

[0287] Preferably, R 1 Selected from ACE, PAL;

[0288] R 2 Selected from NME, -OH, -NH2;

[0289] Preferably, R 2 Selected from NME, -OH;

[0290] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29;

[0291] Preferably, L 1 Selected from P23, P21, P06, P20, P25, P29;

[0292] More preferably, L 1 Selected from P25 and P29.

[0293] In some embodiments, the linear peptide compound has a structure shown in Formula III,

[0294] R 1 -AA 1 -(AA 2 ) n2 -AA a -AA b -AA c -(AA 4 ) n6 -AA 5 -R 2

[0295] Formula III

[0296] in:

[0297] n2 and n6 are each independently selected from 0 and 1;

[0298] Preferably, n2 is 0, and n6 is selected from 0 and 1;

[0299] Or preferably, n2 is selected from 0, 1, and n6 is 0;

[0300] AA a An amino acid residue selected from the group consisting of GLY, LYS, DLYS, LYO, LHY;

[0301] Preferably, AA a selected from the following amino acid residues: GLY, LYS;

[0302] AA b selected from the following amino acid residues: HIS, DHIS;

[0303] Preferably, AA b are the following amino acid residues: HIS;

[0304] AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY, GLY;

[0305] Preferably, AA c An amino acid residue selected from the group consisting of LYS, LYO, LHY, GLY;

[0306] More preferably, AA c selected from the following amino acid residues: LYS, GLY;

[0307] Among them, AA a When the amino acid residues are: GLY, AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY, and AA a When selected from the following amino acid residues: LYS, DLYS, LYO, LHY, AA c is the following amino acid residue: GLY;

[0308] Preferably, AA a -AA b -AA c selected as a whole from the following peptide residues: GLY HIS LYS, LYS HIS GLY, GLY DHISDLYS, GLY HIS LYO, GLY HIS LHI, GLY HIS LHY, GLY HIS LPY;

[0309] R 1 Selected from ACE, PAL, BIO, PEG, VIC;

[0310] Preferably, R 1 Selected from ACE, PAL, BIO;

[0311] R 2 Selected from NME, -OH, -NH2;

[0312] AA 1 Selected from the following amino acid residues: AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, D-M3L;

[0313] Preferably, AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0314] More preferably, AA 1selected from the following amino acid residues: 4PH, ZCL, A30;

[0315] More preferably, AA 1 are the following amino acid residues: M3L;

[0316] AA 2 selected from the following amino acid residues: M3L, 2MR, ALA, GLY;

[0317] Preferably, AA 2 selected from the following amino acid residues: M3L, 2MR;

[0318] Preferably, AA 2 selected from the following amino acid residues: ALA, GLY;

[0319] AA 4 Selected from the following amino acid residues: ALA, GLY, PRO;

[0320] Preferably, AA 4 selected from the following amino acid residues: ALA, GLY;

[0321] AA 5 Selected from the following amino acid residues: M3L, 4PH, ZCL, A30, DOQ, EXL, 0UO, D-4PH, D-ZCL, D-A30;

[0322] Preferably, AA 5 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0323] More preferably, AA 5 selected from the following amino acid residues: 4PH, ZCL, A30;

[0324] More preferably, AA 5 is the following amino acid residue: M3L.

[0325] In some embodiments, the linear peptide compound has a structure shown in Formula III-1,

[0326] R 1 -AA 1 -(AA 2 ) n2 -AA a1 -AA b1 -AA c1 -(AA 4 ) n6 -AA 5 -R 2

[0327] Formula III-1

[0328] in:

[0329] n2 and n6 are each independently selected from 0 and 1;

[0330] Preferably, n2 is 0, and n6 is selected from 0 and 1;

[0331] AA a1 is the following amino acid residue: GLY;

[0332] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0333] Preferably, AA b1 are the following amino acid residues: HIS;

[0334] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY;

[0335] Preferably, AA c1 selected from the following amino acid residues: LYS, LYO, LHY;

[0336] More preferably, AA c1 are the following amino acid residues: LYS;

[0337] Preferably, AA a1 -AA b1 -AA c1 As a whole, selected from the following peptide residues: GLY HIS LYS, GLY DHISDLYS, GLY HIS LYO, GLY HIS LHI, GLY HIS LHY, GLY HIS LPY;

[0338] R 1 Selected from ACE, PAL, BIO, PEG, VIC;

[0339] Preferably, R 1 Selected from ACE, PAL, BIO;

[0340] R 2 Selected from NME, -OH, -NH2;

[0341] AA 1 Selected from the following amino acid residues: AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, D-M3L;

[0342] Preferably, AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0343] More preferably, AA 1 are the following amino acid residues: M3L;

[0344] AA 2 selected from the following amino acid residues: M3L, 2MR;

[0345] AA 4 Selected from the following amino acid residues: ALA, GLY, PRO;

[0346] Preferably, AA 4 selected from the following amino acid residues: ALA, GLY;

[0347] AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30, DOQ, EXL, 0UO, D-4PH, D-ZCL, D-A30;

[0348] Preferably, AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30.

[0349] In some embodiments, the linear peptide compound has a structure shown in Formula III-1-1,

[0350] R 1 -AA 1 -AA a1 -AA b1 -AA c1 -AA 5 -R 2

[0351] Formula III-1-1

[0352] in:

[0353] AA a1 is the following amino acid residue: GLY;

[0354] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0355] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY;

[0356] Preferably, AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0357] Preferably, AA a1 -AA b1 -AA c1As a whole, selected from the following peptide residues: GLY HIS LYS, GLY DHISDLYS, GLY HIS LYO, GLY HIS LHI, GLY HIS LHY, GLY HIS LPY;

[0358] R 1 Selected from ACE, PAL, BIO, PEG, VIC;

[0359] Preferably, R 1 Selected from ACE, PAL, BIO;

[0360] R 2 Selected from NME, -OH, -NH2;

[0361] AA 1 Selected from the following amino acid residues: AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, D-M3L;

[0362] Preferably, AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0363] More preferably, AA 1 are the following amino acid residues: M3L;

[0364] AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30, DOQ, EXL, 0UO, D-4PH, D-ZCL, D-A30;

[0365] Preferably, AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30.

[0366] In some embodiments, the linear peptide compound has a structure shown in Formula III-1-2,

[0367] R 1 -AA 1 -AA a1 -AA b1 -AA c1 -AA 4 -AA 5 -R 2

[0368] Formula III-1-2

[0369] in:

[0370] AA a1 is the following amino acid residue: GLY;

[0371] AAb1 selected from the following amino acid residues: HIS, DHIS;

[0372] Preferably, AA b1 are the following amino acid residues: HIS;

[0373] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY;

[0374] Preferably, AA c1 are the following amino acid residues: LYS;

[0375] Preferably, AA a1 -AA b1 -AA c1 As a whole, the following peptide residues: GLY HIS LYS;

[0376] R 1 Selected from ACE, PAL, BIO, PEG, VIC;

[0377] Preferably, R 1 Selected from ACE, PAL;

[0378] R 2 Selected from NME, -OH, -NH2;

[0379] Preferably, R 2 Selected from NME, -OH;

[0380] AA 1 selected from the following amino acid residues: M3L, MLZ, MLY;

[0381] Preferably, AA 1 are the following amino acid residues: M3L;

[0382] AA 4 Selected from the following amino acid residues: ALA, GLY, PRO;

[0383] Preferably, AA 4 selected from the following amino acid residues: ALA, GLY;

[0384] AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30.

[0385] In some embodiments, the linear peptide compound has a structure shown in Formula III-1-3,

[0386] R 1 -AA 1 -AA 2 -AAa1 -AA b1 -AA c1 -AA 4 -AA 5 -R 2

[0387] Formula III-1-3

[0388] in:

[0389] AA a1 is the following amino acid residue: GLY;

[0390] AA b1 selected from the following amino acid residues: HIS, DHIS;

[0391] Preferably, AA b1 are the following amino acid residues: HIS;

[0392] AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY;

[0393] Preferably, AA c1 are the following amino acid residues: LYS;

[0394] Preferably, AA a1 -AA b1 -AA c1 As a whole, the following peptide residues: GLY HIS LYS;

[0395] R 1 Selected from ACE, PAL, BIO, PEG, VIC;

[0396] Preferably, R 1 For ACE;

[0397] R 2 Selected from NME, -OH, -NH2;

[0398] Preferably, R 2 For NME;

[0399] AA 1 selected from the following amino acid residues: M3L, 2MR;

[0400] AA 2 selected from the following amino acid residues: M3L, 2MR;

[0401] AA 4 are the following amino acid residues: ALA;

[0402] AA 5Selected from 4PH, ZCL, A30.

[0403] In some embodiments, the linear peptide compound has a structure shown in Formula III-2,

[0404] R 1 -AA 1 -(AA 2 ) n2 -AA a2 -AA b2 -AA c2 -AA 5 -R 2

[0405] Formula III-2

[0406] in:

[0407] n2 is selected from 0 and 1;

[0408] AA a2 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0409] Preferably, AA a2 are the following amino acid residues: LYS;

[0410] AA b2 selected from the following amino acid residues: HIS, DHIS;

[0411] Preferably, AA b2 are the following amino acid residues: HIS;

[0412] AA c2 is the following amino acid residue: GLY;

[0413] Preferably, AA a2 -AA b2 -AA c2 As a whole, the following peptide residues: LYS HIS GLY;

[0414] R 1 Selected from ACE, PAL, BIO, PEG, VIC;

[0415] Preferably, R 1 Selected from ACE, PAL, BIO;

[0416] Preferably, R 1 For ACE;

[0417] R 2 Selected from NME, -OH, -NH2;

[0418] Preferably, R 2For NME;

[0419] AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0420] Preferably, AA 1 selected from the following amino acid residues: 4PH, ZCL, A30;

[0421] AA 2 selected from the following amino acid residues: ALA, GLY;

[0422] AA 5 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0423] Preferably, AA 5 is the following amino acid residue: M3L.

[0424] In some embodiments, the linear peptide compound has the structure shown in Formula III-2-1,

[0425] R 1 -AA 1 -AA a2 -AA b2 -AA c2 -AA 5 -R 2

[0426] Formula III-2-1

[0427] in:

[0428] AA a2 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0429] Preferably, AA a2 are the following amino acid residues: LYS;

[0430] AA b2 selected from the following amino acid residues: HIS, DHIS;

[0431] Preferably, AA b2 are the following amino acid residues: HIS;

[0432] AA c2 is the following amino acid residue: GLY;

[0433] Preferably, AA a2 -AA b2 -AA c2 As a whole, the following peptide residues: LYS HIS GLY;

[0434] R 1 Selected from ACE, PAL, BIO, PEG, VIC;

[0435] Preferably, R 1 For ACE;

[0436] R 2 Selected from NME, -OH, -NH2;

[0437] Preferably, R 2 For NME;

[0438] AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0439] Preferably, AA 1 Select the following amino acid residues: 4PH, ZCL, A30;

[0440] AA 5 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0441] Preferably, AA 5 is the following amino acid residue: M3L.

[0442] In some embodiments, the linear peptide compound has the structure shown in Formula III-2-2,

[0443] R 1 -AA 1 -AA 2 -AA a2 -AA b2 -AA c2 -AA 5 -R 2

[0444] Formula III-2-2

[0445] AA a2 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY;

[0446] Preferably, AA a2 are the following amino acid residues: LYS;

[0447] AA b2 selected from the following amino acid residues: HIS, DHIS;

[0448] Preferably, AA b2 are the following amino acid residues: HIS;

[0449] AA c2 is the following amino acid residue: GLY;

[0450] Preferably, AA a2 -AA b2 -AA c2 As a whole, the following peptide residues: LYS HIS GLY;

[0451] R 1 Selected from ACE, PAL, BIO;

[0452] R 2 Selected from NME, -OH, -NH2;

[0453] AA 1 selected from the following amino acid residues: 4PH, ZCL, A30;

[0454] AA 2 selected from the following amino acid residues: ALA, GLY;

[0455] AA 5 is the following amino acid residue: M3L.

[0456] In some embodiments, the linear peptide compound has a structure shown in Formula IV,

[0457] R 1 -(AA 1 ) n1 -(L 1 ) n3 -AA a -AA b -AA c -(AA 5 ) n7 -R 2

[0458] Formula IV

[0459] in:

[0460] n1, n3, and n7 are each independently selected from 0 and 1, and are not 0 at the same time;

[0461] Preferably, n1 and n7 are selected from 0, and n3 is selected from 1; or n1 and n7 are selected from 1; n3 is selected from 0; or n1 and n3 are selected from 1, and n7 is selected from 0;

[0462] AA a -AA b -AA c As a whole, selected from the following peptide residues: LYS HIS GLY, GLY HIS LYS, GLY HIS LYO, GLY HIS LHY;

[0463] Preferred AA a -AAb -AA c As a whole, selected from the following peptide residues: LYS HIS GLY, GLY HIS LYS, GLY HIS LYO;

[0464] AA 1 Selected from the following amino acid residues: M3L, AGM, NMM, 2MR, MLZ, MLY, 4PH, ZCL, A30, D-M3L;

[0465] Preferably, AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30;

[0466] Preferably, AA 1 selected from the following amino acid residues: M3L, 4PH;

[0467] Preferably, AA 1 selected from the following amino acid residues: M3L;

[0468] AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30, DOQ, EXL, 0UO, M3L, D-4PH, D-ZCL, D-A30;

[0469] Preferably, AA 5 selected from the following amino acid residues: 4PH, ZCL, A30, M3L;

[0470] Preferably, AA 5 selected from the following amino acid residues: 4PH, A30, M3L;

[0471] Preferably, AA 5 selected from the following amino acid residues: 4PH;

[0472] Preferably, AA 5 selected from the following amino acid residues: A30;

[0473] L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0474] Preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29;

[0475] Preferably, L 1 Selected from P21, P06, P23, P25, P20;

[0476] Preferably, L 1 Selected from P21, P06, P25, P23;

[0477] R 1 Selected from ACE, PAL, BIO, PEG, VIC;

[0478] Preferably, R 1 Selected from ACE, PAL, BIO;

[0479] Preferably, R 1 Selected from ACE, PAL;

[0480] More preferably, R 1 Selected from ACE;

[0481] R 2 Selected from NME, -OH, -NH2;

[0482] Preferably, R 2 Selected from NME, -OH;

[0483] More preferably, R 2 Selected from NME.

[0484] In some embodiments, the linear peptide compound has the structure shown in Formula Ia,

[0485] R 1 -GLY-HIS-LYS-L 2 -GLY-HIS-LYS-R 2 (SEQ ID NO:433)

[0486] Formula Ia

[0487] in:

[0488] R 1 , L 2 、R 2 As defined in any of the above embodiments;

[0489] Preferably, L 2 Selected from P01, P02, P03, P04, P05, P06, P07, P08, P19, P20, P21, P22, P23;

[0490] More preferably, L 2 Selected from P05, P06, P07, P08, P19, P20, P21, P22, P23;

[0491] More preferably, L 2 Selected from P06, P21, and P23.

[0492] In some embodiments, the linear peptide compound has any one of the structures shown in Formula II-a to II-o:

[0493] R 1 -L 1 -GLY-HIS-LYS-R 2

[0494] Formula II-a

[0495] R 1 -AA 1 -L 1 -GLY-HIS-LYS-R 2

[0496] Formula II-b

[0497] R 1 -L 1 -AA 3 -GLY-HIS-LYS-R 2

[0498] Formula II-c

[0499] R 1 -AA 1 -AA 2 -L 1 -GLY-HIS-LYS-R 2

[0500] Formula II-d

[0501] R 1 -L 1 -GLY-HIS-LYS-AA 5 -R 2

[0502] Formula II-e

[0503] R 1 -L 1 -GLY-HIS-LYS-AA 4 -AA 5 -R 2

[0504] Formula II-f

[0505] R 1 -AA 1 -L 1 -GLY-HIS-LYS-AA 4 -AA 5 -R 2

[0506] Formula II-g

[0507] R 1 -L 1 -GLY-DHIS-DLYS-R 2

[0508] Formula II-h

[0509] R 1 -AA 1 -L 1 -GLY-DHIS-DLYS-R 2

[0510] Formula II-i

[0511] R 1 -L 1 -GLY-HIS-LYO-R 2

[0512] Formula II-j

[0513] R 1 -AA 1 -L 1 -GLY-HIS-LYO-R 2

[0514] Formula II-k

[0515] R 1 -L 1 -GLY-HIS-LHY-R 2 <00值1941>

[0516] Formula II-l

[0517] R 1 -AA 1 -L 1 -GLY-HIS-LHY-R 2

[0518] Formula II-m

[0519] R 1 -L 1 -LYS-HIS-GLY-R 2

[0520] Formula II-n

[0521] R 1 -AA 1 -L 1 -LYS-HIS-GLY-R 2

[0522] Formula II-o

[0523] Among them, R 1 , L 1 、R 2 AA 1 AA 2 AA 3 AA 4 AA 5 As defined in any embodiment above.

[0524] In some embodiments, the linear peptide compound has the structure shown in Formula II-n.

[0525] In some embodiments, the linear peptide compound has a structure shown in Formula II-a.

[0526] In some embodiments, the linear peptide compound has the structure shown in Formula II-b.

[0527] In some embodiments, the linear peptide compound has the structure shown in Formula II-1.

[0528] In some embodiments, the linear peptide compound has the structure shown in Formula II-k.

[0529] In some embodiments, in Formula II-a, preferably R 1 Selected from ACE, PAL, BIO; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29; R 2 Selected from NME, -OH, -NH2; More preferably R 1 Selected from PAL, BIO; L 1 Selected from P25; R 2 Selected from -OH, -NH2.

[0530] In some embodiments, in Formula II-b, preferably R 1 Selected from ACE, PAL, AA 1 Selected from M3L, 4PH; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29; R 2 Selected from NME, -OH; more preferably R 1 Selected from PAL;AA 1 Selected from M3L; L 1 Selected from P23; R 2 Selected from -OH.

[0531] In some embodiments, in Formula II-c, preferably R 1 Selected from ACE, PAL, BIO; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29; AA 3 Selected from M3L; R 2 Selected from NME, -OH, -NH2.

[0532] In some embodiments, in Formula II-d, preferably R 1 Selected from ACE;AA 1 Selected from 4PH, ZCL, A30; AA 2 Selected from M3L; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20; R 2 Selected from NME.

[0533] In some embodiments, in Formula II-e, preferably R 1 Selected from ACE;L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20; AA 5 Selected from 4PH; R 2 Selected from NME.

[0534] In some embodiments, in Formula II-f, preferably R 1 Selected from ACE;L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20; AA 4 Selected from GLY, ALA; AA 5 Selected from 4PH; R 2 Selected from NME.

[0535] In some embodiments, in Formula II-g, preferably R 1 Selected from ACE;AA 1 Selected from M3L; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20; AA 4 Selected from ALA; AA 5 Selected from 4PH; R 2 Selected from NME.

[0536] In some embodiments, in Formula II-h, preferably R 1 Selected from ACE, PAL, BIO; L 1Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29; R 2 Selected from NME, -OH, -NH2.

[0537] In some embodiments, in Formula II-i, preferably R 1 Selected from ACE, PAL, AA 1 Selected from M3L; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29; R 2 Selected from NME, -OH.

[0538] In some embodiments, in Formula II-j, preferably R 1 Selected from ACE;L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20; R 2 Selected from NME.

[0539] In some embodiments, in Formula II-k, preferably R 1 Selected from ACE, BIO; AA 1 Selected from M3L; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20; R 2 is selected from NME, -NH2; more preferably, R 1 Selected from BIO;AA 1 Selected from M3L; L 1 Selected from P06; R 2 Selected from -NH2.

[0540] In some embodiments, in Formula II-1, preferably R 1 Selected from ACE, PAL, BIO; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20; R 2 Selected from NME, -OH, -NH2; More preferably R 1 Selected from PAL;L 1 Selected from P21; R 2 Selected from -OH.

[0541] In some embodiments, in Formula II-m, preferably R 1 Selected from ACE;AA 1 Selected from M3L; L 1Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20; R 2 Selected from NME.

[0542] In some embodiments, in Formula II-n, preferably R 1 Selected from ACE, PAL, BIO; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29; R 2 Selected from NME, -OH, -NH2; More preferably R 1 Selected from ACE, PAL, BIO; L 1 Selected from P06, P21, P25, ; R 2 Selected from NME, -OH, -NH2.

[0543] In some embodiments, in Formula II-o, preferably R 1 Selected from ACE, PAL, AA 1 Selected from M3L; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29; R 2 Selected from NME, -OH.

[0544] In some embodiments, the linear peptide compound has any one of the structures shown in Formula III-a to III-j:

[0545] R 1 -AA 1 -GLY-HIS-LYS-AA 5 -R 2

[0546] Formula III-a

[0547] R 1 -AA 1 -GLY-HIS-LYO-AA 5 -R 2

[0548] Formula III-b

[0549] R 1 -AA 1 -GLY-HIS-LYS-AA 4 -AA 5 -R 2

[0550] Formula III-c

[0551] R1 -AA 1 -AA 2 -GLY-HIS-LYS-AA 4 -AA 5 -R 2

[0552] Formula III-d

[0553] R 1 -AA 1 -LYS-HIS-GLY-AA 5 -R 2

[0554] Formula III-e

[0555] R 1 -AA 1 -GLY-DHIS-DLYS-AA 5 -R 2

[0556] Formula III-f

[0557] R 1 -AA 1 -GLY-HIS-LHI-AA 5 -R 2

[0558] Formula III-g

[0559] R[[ID=)56]] 1 -AA 1 -GLY-HIS-LHY-AA 5 -R 2

[0560] Formula III-h

[0561] R 1 -AA 1 -GLY-HIS-LPY-AA 5 -R 2

[0562] Formula III-i

[0563] R 1 -AA 1 -AA 2 -LYS-HIS-GLY-AA 5 -R 2

[0564] Formula III-j

[0565] wherein, R 1 、AA 1 、AA2 AA 4 AA 5 、R 2 As defined in any of the above embodiments.

[0566] In some embodiments, the linear peptide compound has the structure shown in Formula III-b.

[0567] In some embodiments, the linear peptide compound has the structure shown in Formula III-c.

[0568] In some embodiments, the linear peptide compound has the structure shown in Formula III-e.

[0569] In some embodiments, the linear peptide compound has the structure shown in Formula III-h.

[0570] In some embodiments, the linear peptide compound has the structure shown in Formula III-j.

[0571] In some embodiments, in Formula III-a, preferably R 1 Selected from ACE, PAL, BIO, PEG, VIC; AA 1 Selected from AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, D-M3L; AA 5 Selected from 4PH, ZCL, A30, D0Q, EXL, 0UO, D-4PH, D-ZCL, D-A30; R 2 Selected from NME, -OH, -NH2.

[0572] In some embodiments, in Formula III-b, preferably R 1 Selected from ACE, PAL, BIO; AA 1 Selected from M3L;AA 5 Selected from 4PH, ZCL, A30; R 2 Selected from NME, -OH, -NH2; More preferably R 1 Selected from ACE, PAL, AA 1 Selected from M3L;AA 5 Selected from 4PH, A30; R 2 Selected from NME, -OH.

[0573] In some embodiments, in Formula III-c, preferably R 1 Selected from ACE, PAL, AA 1 Selected from M3L, MLZ, MLY; AA 4 Selected from ALA, GLY, PRO; AA 5 Selected from 4PH, ZCL, A30; R 2Selected from NME, -OH; more preferably R 1 Selected from ACE, PAL, AA 1 Selected from M3L;AA 4 Selected from ALA, GLY; AA 5 Selected from 4PH, ZCL; R 2 Selected from NME, -OH.

[0574] In some embodiments, in Formula III-d, preferably R 1 Selected from ACE;AA 1 Selected from M3L, 2MR, AA 2 Selected from 2MR, M3L, AA 4 Selected from ALA; AA 5 Selected from 4PH, ZCL, A30; R 2 Selected from NME.

[0575] In some embodiments, in Formula III-e, preferably R 1 Selected from ACE;AA 1 Selected from M3L, 4PH, ZCL, A30; AA 5 Selected from 4PH, ZCL, A30, M3L; R 2 Selected from NME; more preferably R 1 Selected from ACE;AA 1 Selected from 4PH; AA 5 Selected from M3L; R 2 Selected from NME.

[0576] In some embodiments, in Formula III-f, preferably R 1 Selected from ACE;AA 1 Selected from M3L, D-M3L; AA 5 Selected from 4PH, ZCL, A30, D-4PH, D-ZCL, D-A30; R 2 Selected from NME.

[0577] In some embodiments, in Formula III-g, preferably R 1 Selected from ACE;AA 1 Selected from M3L;AA 5 Selected from 4PH, ZCL, A30; R 2 Selected from NME.

[0578] In some embodiments, in Formula III-h, preferably R 1 Selected from ACE, PAL, BIO; AA 1 Selected from M3L;AA 5 Selected from 4PH, ZCL, A30; R 2Selected from NME, -OH, -NH2; More preferably R 1 Selected from ACE, PAL, BIO; AA 1 Selected from M3L;AA 5 Selected from 4PH; R 2 Selected from NME, -OH, -NH2.

[0579] In some embodiments, in Formula III-i, preferably R 1 Selected from ACE;AA 1 Selected from M3L;AA 5 Selected from 4PH, ZCL, A30; R 2 Selected from NME.

[0580] In some embodiments, in Formula III-j, preferably R 1 Selected from ACE, PAL, BIO; AA 1 Selected from 4PH, ZCL, A30; AA 2 Selected from ALA, GLY; AA 5 Selected from M3L; R 2 Selected from NME, -OH, -NH2; More preferably R 1 Selected from PAL, BIO; AA 1 Selected from 4PH, ZCL, A30; AA 2 Selected from ALA; AA 5 Selected from M3L; R 2 Selected from -OH, -NH2.

[0581] In some embodiments, the structure of the linear peptide compound is as shown in Table A.

[0582] Table A: Structural formula of linear peptide compounds

[0583] In some embodiments, the structure of the linear peptide compound is as shown in Table A-1.

[0584] Table A-1: ​​Structural formula of linear peptide compounds

[0585] In some embodiments, the structure of the linear peptide compound is shown in Table A-2.

[0586] Table A-2: Structural formula of linear peptide compounds

[0587] In some embodiments, the structure of the linear peptide compound is as shown in Table B-1 and Table B-3 or as shown in Table B-2 and Table B-3.

[0588] In some embodiments, the structure of the linear peptide compound is shown in Table B-1.

[0589] In some embodiments, the structure of the linear peptide compound is shown in Table B-2.

[0590] In some embodiments, the structure of the linear peptide compound is shown in Table B-3.

[0591] Table B-1: Structural formulas of preferred linear peptide compounds

[0592] Table B-2: Structural formulas of preferred linear peptide compounds

[0593] Table B-3: Structural formula of preferred linear peptide compounds

[0594] In some embodiments, the structures of the linear peptide compounds are shown in Table C-1 and Table C-2.

[0595] In some embodiments, the structure of the linear peptide compound is shown in Table C-1.

[0596] In some embodiments, the structure of the linear peptide compound is shown in Table C-2.

[0597] Table C-1: More preferred linear peptide compound structures

[0598] Table C-2: More preferred linear peptide compound structures

[0599] In some embodiments, the structure of the linear peptide compound is as shown in Table D.

[0600] Table D: Most preferred linear peptide compound structure

[0601] In some embodiments, the structure of the linear peptide compound is shown in Table D-1.

[0602] Table D-1: Most preferred linear peptide compound structure

[0603] In some embodiments, the structure of the linear peptide compound is as shown in Table D-2.

[0604] Table D-2: Most preferred linear peptide compound structure

[0605] In the second aspect of the present invention, the present invention provides a pharmaceutical composition comprising the aforementioned linear peptide compound or a stereoisomer thereof.

[0606] In some embodiments, the pharmaceutical composition further comprises at least one carrier and / or excipient.

[0607] In the third aspect of the present invention, the present invention provides a cosmetic composition (such as a skin care product, a cosmetic, a hair growth liquid, etc.), which comprises the aforementioned linear peptide compound or a stereoisomer thereof.

[0608] In some embodiments, the cosmetic composition further comprises a functional substance.

[0609] In some embodiments, the functional substance is selected from one or more of a skin conditioner, an antioxidant, a surfactant, a moisturizer, a preservative, a chelating agent, and a fragrance.

[0610] In a fourth aspect of the present invention, the present invention provides the use of the aforementioned linear peptide compound or its stereoisomer or the aforementioned pharmaceutical composition in the preparation of a medicament, wherein the medicament is used for one or more selected from the following (1)-(7):

[0611] (1) Delay skin aging;

[0612] (2) Reduce skin damage;

[0613] (3) Accelerate skin wound healing;

[0614] (4) Reduce hyperpigmentation;

[0615] (5) stimulate hair growth;

[0616] (6) Improve the success rate of hair transplantation;

[0617] (7) Prevent hair loss.

[0618] In a fifth aspect of the present invention, the present invention provides the aforementioned linear peptide compound or its stereoisomer or the aforementioned pharmaceutical composition, for use in one or more of the following (1)-(7):

[0619] (1) Delay skin aging;

[0620] (2) Reduce skin damage;

[0621] (3) Accelerate skin wound healing;

[0622] (4) Reduce hyperpigmentation;

[0623] (5) stimulate hair growth;

[0624] (6) Improve the success rate of hair transplantation;

[0625] (7) Prevent hair loss.

[0626] In a sixth aspect, the present invention provides a method selected from one or more of the following (1) to (7), comprising: administering an effective amount of the aforementioned linear peptide compound or its stereoisomer or the aforementioned pharmaceutical composition to a subject in need thereof,

[0627] (1) Methods for delaying skin aging;

[0628] (2) Methods to reduce skin damage;

[0629] (3) Methods for accelerating skin wound healing;

[0630] (4) methods to reduce hyperpigmentation;

[0631] (5) Methods of stimulating hair growth;

[0632] (6) Methods to improve the success rate of hair transplantation;

[0633] (7) Methods to prevent hair loss.

[0634] In a seventh aspect, the present invention provides a use of the aforementioned linear peptide compound or its stereoisomer or the aforementioned cosmetic composition for one or more selected from the following (1)-(17), wherein the use is a non-therapeutic use:

[0635] (1) Anti-aging of the skin;

[0636] (2) Anti-wrinkle and reduce fine lines;

[0637] (3) Improve the mechanical properties of the skin: firmness, skin tone, elasticity and / or flexibility;

[0638] (4) Improve skin density (reconstruction effect);

[0639] (5) Increase skin volume (plumping effect);

[0640] (6) Counteract the appearance of stretch marks;

[0641] (7) Reduce skin damage;

[0642] (8) Accelerate skin wound healing;

[0643] (9) Anti-spot;

[0644] (10) Improve skin homogeneity and / or radiance;

[0645] (11) Reduce skin pigmentation;

[0646] (12) Moisturizing;

[0647] (13) Stimulate hair growth;

[0648] (14) Improve the success rate of hair transplantation;

[0649] (15) Prevent hair loss;

[0650] (16) Local beauty treatment of eyelashes;

[0651] (7) Increase hair width, density and / or length.

[0652] In an eighth aspect, the present invention provides a method selected from one or more of the following (1) to (17), comprising: administering an effective amount of the aforementioned linear peptide compound or its stereoisomer or the aforementioned cosmetic composition to a subject in need thereof,

[0653] (1) Methods for skin anti-aging;

[0654] (2) Methods for anti-wrinkle and fine line reduction;

[0655] (3) Methods to improve the mechanical properties of the skin: firmness / skin tone / elasticity / flexibility;

[0656] (4) methods to increase skin density (reconstruction effect);

[0657] (5) Methods for increasing skin volume (volumizing effect);

[0658] (6) Methods to combat the appearance of stretch marks;

[0659] (7) Methods to reduce skin damage;

[0660] (8) Methods for accelerating skin wound healing;

[0661] (9) Anti-spot methods;

[0662] (10) Methods for improving skin homogeneity and / or radiance;

[0663] (11) Methods for reducing skin pigmentation;

[0664] (12) Moisturizing methods;

[0665] (13) Methods of stimulating hair growth;

[0666] (14) Methods to improve the success rate of hair transplantation;

[0667] (15) Methods for preventing hair loss;

[0668] (16) Local cosmetic methods for eyelashes;

[0669] (17) Methods for increasing hair width, density and / or length.

[0670] In the ninth aspect of the present invention, the present invention provides the use of the aforementioned linear peptide compound or its stereoisomer or the aforementioned cosmetic composition for one or more selected from the following (1)-(17):

[0671] (1) Anti-aging of the skin;

[0672] (2) Anti-wrinkle and reduce fine lines;

[0673] (3) Improve the mechanical properties of the skin: firmness, skin tone, elasticity and / or flexibility;

[0674] (4) Improve skin density (reconstruction effect);

[0675] (5) Increase skin volume (plumping effect);

[0676] (6) Combat the appearance of stretch marks;

[0677] (7) Reduce skin damage;

[0678] (8) Accelerate skin wound healing;

[0679] (9) Anti-spot;

[0680] (10) Improve skin homogeneity and / or radiance;

[0681] (11) Reduce skin pigmentation;

[0682] (12) Moisturizing;

[0683] (13) Stimulate hair growth;

[0684] (14) Improve the success rate of hair transplantation;

[0685] (15) Prevent hair loss;

[0686] (16) Local beauty treatment of eyelashes;

[0687] (7) Increase hair width, density and / or length. Beneficial effects

[0688] 1. The linear peptide compounds of the present invention (e.g., the linear peptide compounds in Table A, or Table A-1, Table A-2, or Table B-1, Table B-2, Table B-3, or any combination thereof, or Table C-1, Table C-2, or Table D, or Table D-1, Table D-2) or their stereoisomers can achieve anti-wrinkle effects by significantly increasing the content of Collagen I.

[0689] 2. The linear peptide compounds of the present invention (e.g., the linear peptide compounds in Table A, or Table A-1, Table A-2, or Table B-1, Table B-2, Table B-3, or any combination thereof, or Table C-1, Table C-2, or Table D, or Table D-1, Table D-2) or their stereoisomers can significantly increase the hyaluronic acid (HA) content, thereby achieving a firming effect.

[0690] 3. The linear peptide compounds of the present invention (e.g., the linear peptide compounds in Table A, or Table A-1, Table A-2, or Table B-1, Table B-2, Table B-3, or any combination thereof, or Table C-1, Table C-2, or Table D, or Table D-1, Table D-2) or their stereoisomers can significantly increase the elastin content, thereby achieving a firming effect.

[0691] 4. The linear peptide compounds of the present invention (e.g., the linear peptide compounds in Table A, or Table A-1, Table A-2, or Table B-1, Table B-2, Table B-3, or any combination thereof, or Table C-1, Table C-2, or Table D, or Table D-1, Table D-2) or their stereoisomers can significantly increase the content of Collagen I, hyaluronic acid (HA), and elastin, thereby achieving anti-wrinkle and firming effects, and having excellent medical and cosmetic effects.

[0692] 5. The linear peptide compounds of the present invention (e.g., the linear peptide compounds in Table A, or Table A-1, Table A-2, or Table B-1, Table B-2, Table B-3, or any combination thereof, or Table C-1, Table C-2, or Table D, or Table D-1, Table D-2) do not exhibit significant cytotoxicity (e.g., within a concentration range of 5 μM) and have good prospects for application in medicine and cosmetics.

[0693] 6. The linear peptide compounds of the present invention (e.g., the linear peptide compounds in Table A, or Table A-1, Table A-2, or Table B-1, Table B-2, Table B-3, or any combination thereof, or Table C-1, Table C-2, or Table D, or Table D-1, Table D-2) or their stereoisomers, when used as medicine, have one or more beneficial effects selected from the following:

[0694] (1) Delay skin aging;

[0695] (2) Reduce skin damage;

[0696] (3) Accelerate skin wound healing;

[0697] (4) Reduce hyperpigmentation;

[0698] (5) stimulate hair growth;

[0699] (6) Improve the success rate of hair transplantation;

[0700] (7) Prevent hair loss.

[0701] 7. The linear peptide compounds of the present invention (e.g., the linear peptide compounds in Table A, or Table A-1, Table A-2, or Table B-1, Table B-2, Table B-3, or any combination thereof, or Table C-1, Table C-2, or Table D, or Table D-1, Table D-2) or their stereoisomers, when used for cosmetic or non-therapeutic purposes, have one or more beneficial effects selected from the following:

[0702] (1) Anti-aging of the skin;

[0703] (2) Anti-wrinkle and reduce fine lines;

[0704] (3) Improve the mechanical properties of the skin: firmness, skin tone, elasticity and / or flexibility;

[0705] (4) Improve skin density (reconstruction effect);

[0706] (5) Increase skin volume (plumping effect);

[0707] (6) Combat the appearance of stretch marks;

[0708] (7) Reduce skin damage;

[0709] (8) Accelerate skin wound healing;

[0710] (9) Anti-spot;

[0711] (10) Improve skin homogeneity and / or radiance;

[0712] (11) Reduce skin pigmentation;

[0713] (12) Moisturizing;

[0714] (13) Stimulate hair growth;

[0715] (14) Improve the success rate of hair transplantation;

[0716] (15) Prevent hair loss;

[0717] (16) Local beauty treatment of eyelashes;

[0718] (17) Increase hair width, density and / or length.

[0719] 8. The linear peptide compounds of the present invention (e.g., the linear peptide compounds in Table A, or Table A-1, Table A-2, or Table B-1, Table B-2, Table B-3, or any combination thereof, or Table C-1, Table C-2, or Table D, or Table D-1, Table D-2) or their stereoisomers have comparable or even better efficacy than GHK tripeptide in the above seven aspects. DETAILED DESCRIPTION

[0720] The embodiments of the present invention will be described in detail below with reference to the examples, but it will be understood by those skilled in the art that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention. Where specific conditions are not specified in the examples, the methods were performed according to conventional conditions or the conditions recommended by the manufacturer. Where the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be obtained commercially.

[0721] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, terms and laboratory procedures related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used herein are those widely used in the respective fields and are standard procedures. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.

[0722] The term "stereoisomer" refers to a compound with the same molecular formula in which the atoms or substituents are connected in the same order but arranged in space in different ways, which is a phenomenon of isomerism in the field of organic chemistry.

[0723] The term "carrier" refers to a system that can change the way a drug enters the human body and its distribution within the body, control the rate of drug release, and deliver the drug to a targeted organ. Drug carrier release and targeting systems can reduce drug degradation and loss, reduce side effects, and improve bioavailability. For example, polymer surfactants that can be used as carriers can self-assemble to form various forms of aggregates due to their unique amphiphilic structure. Preferred examples include micelles, microemulsions, gels, liquid crystals, and vesicles. These aggregates have the ability to encapsulate drug molecules while also having good membrane permeability, making them excellent drug carriers.

[0724] The term "excipient" refers to an additive other than the main drug in a pharmaceutical preparation, which may also be called an excipient. Excipients include, but are not limited to: ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human albumin, buffer substances such as phosphates, glycerol, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, beeswax, lanolin, etc.

[0725] The term "skin conditioning agent" includes, but is not limited to, hydroquinone, kojic acid, arbutin, ellagic acid, azelaic acid, azeloyl diglycine, L-ascorbic acid and its derivatives, licorice extract, magnolia officinalis fruit extract, hydrangea extract, alkoxysalicylic acid, knotweed extract, sophora japonica flower extract, turmeric extract, mulberry bark extract, emblica fruit extract, pea extract, aloin, and the like.

[0726] The term "antioxidant" includes, but is not limited to, butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, octyl gallate, lauryl gallate, t-butylhydroquinone, tocopherol, ascorbyl palmitate, isopropyl citrate mixture, monoglyceride citrate, anoxomer, sodium sulfite, sodium bisulfite, sodium metabisulfite, cysteine, isoascorbic acid, thiourea, dilauryl thiomalonate, nordihydroguaiaretic acid, lipoic acid, alpha-tocopheryl acetate, carotenoids, emblica tannins, ascorbic acid, glutathione, coenzyme Q10, and the like.

[0727] The term "surfactant" may include anionic surfactants, cationic surfactants, nonionic surfactants, amphoteric surfactants, natural surfactants, fluorine-containing surfactants, and the like.

[0728] The term "humectant" includes, but is not limited to, glycerin, propylene glycol, butylene glycol, sorbitol, sorbitol polyether-20, amide moisturizers, glyceryl polyether moisturizers, lactic acid and sodium lactate, sodium pyrrolidone carboxylate, hydroxyethyl urea, erythritol, glyceryl polyether-5 lactate, sodium hyaluronate, saccharide isomers, D-panthenol, polyethylene glycol, diglycerin, methacryloyloxyethyl phosphorylcholine, etc.

[0729] The term "preservative" includes but is not limited to hydroxyphenyl esters and their salts, formaldehyde and formaldehyde donors, isothiazolinones, phenolic preservatives, acid preservatives, halide preservatives, quaternary ammonium compounds, alcohols, commonly used compound preservatives and natural preservatives, etc.

[0730] The term "chelating agent" may be selected from ethylenediaminetetraacetic acid and its sodium salt, glycine, citric acid, succinic acid and the like.

[0731] The term "essence" can specifically be sandalwood, jasmine, rose, sweet orange, vanilla essence, etc. Essence can also include essential oils, specifically lime peel oil, petitgrain leaf / twig oil, geranium oil, Damascus rose flower oil, etc.

[0732] The term "treat" generally refers to obtaining a desired pharmacological and / or physiological effect. The effect can be prophylactic, in terms of completely or partially preventing a disease or its symptoms; and / or therapeutic, in terms of partially or completely stabilizing or curing a disease and / or causing side effects due to the disease. As used herein, "treat" encompasses any treatment of a disease in a patient, including: (a) preventing the onset of a disease or symptom in a patient who is susceptible to the disease or symptom but has not yet been diagnosed with the disease; (b) suppressing the symptoms of a disease, i.e., arresting its development; or (c) relieving the symptoms of a disease, i.e., causing the disease or symptom to regress.

[0733] The term "subject" includes humans and non-human animals. In the present invention, the term "non-human animal" includes all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).

[0734] The term "effective amount" refers to an amount effective to achieve the desired effect at the necessary dosage and time. The "effective amount" of the present invention may vary depending on factors such as individual skin / hair condition, age, sex and weight.

[0735] In the present invention, the 20 conventional amino acids and their abbreviations follow conventional usage. See Immunology—A Synthesis (2nd edition, ES Golub and DR Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference.

[0736] It is well known to those skilled in the art that the term "amino acid residue" refers to the incomplete amino acid structure remaining after the amino group of an amino acid loses a hydrogen and the carboxyl group loses a hydroxyl, and has an amino terminus (N-terminus) and a carboxyl terminus (C-terminus).

[0737] In the linear peptide compounds of the present invention, unless otherwise specified, the N-terminus to the C-terminus are assumed to be from left to right, and those skilled in the art will understand that each linking group is connected to each amino acid residue by a peptide bond. For example, taking the linear peptide compound BIO P06 LYS HIS GLY NH2 shown in SEQ ID NO: 242 as an example, the left side is assumed to be the N-terminus and the right side is the C-terminus, and the linking group is connected to the amino acid residue by a peptide bond. Therefore, the chemical structure of P06 LYS HIS GLY is Obviously, in this structure, P06 and LYS are connected by a peptide bond. Furthermore, the left side (N-terminus) of the structure is connected to the end-capping group BIO, and the right side (C-terminus) is connected to the end-capping group NH2, forming a linear peptide compound BIO P06 LYS HIS GLY NH2, whose structural formula is

[0738] In the linear peptide compounds of the present invention, if D or D- is added before an amino acid residue, it means that the amino acid residue is D-type. Correspondingly, if D or D- is not added before an amino acid residue, it is assumed to be L-type (GLY has no chiral center, therefore, GLY is excluded).

[0739] In the present invention, the meanings of the abbreviations are shown in Table E below.

[0740] Table E: Meaning of each abbreviation in the present invention

[0741] In addition, the abbreviations in the examples have conventional meanings known in the art and are listed as follows:

[0742] AcOH, Acetic Acid, Acetic Acid

[0743] ACN, Acetonitrile, acetonitrile

[0744] DCM, Dichloromethane (Methylene chloride)

[0745] DMF, N,N-Dimethylformamide, N,N-dimethylformamide

[0746] DIEA, N,N-Diisopropylethylamine, N,N-Diisopropylethylamine

[0747] Fmoc, 9-fluorenylmethyloxycarbonyl, 9-fluorenylmethyloxycarbonyl

[0748] HOBT, 1-Hydroxybenzotriazole

[0749] Piperidine

[0750] PyBOP, Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate

[0751] Resin

[0752] TBTU, O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate

[0753] TFA, Trifluoroacetic acid

[0754] TFE, 2,2,2-Trifluoroethanol

[0755] TIS, Triisopropylsilane, Fmoc-7-Ahp-OH, FMOC-7-AMINO-HEPTANOIC ACID, 7-(Fluorenylmethyloxycarbonyl-amino)heptanoic acid

[0756] The present invention will be further explained below in conjunction with specific examples, but they should not be construed as limiting the present invention in any way. In addition, unless otherwise specified, all raw materials or reagents can be purchased commercially.

[0757] Example 1: Synthesis and identification of linear peptide compounds

[0758] 1. Synthesis of linear peptide compounds

[0759] Taking the linear peptide compound shown in SEQ ID NO: 242 (BIO P06 LYS HIS GLY NH2) as an example, starting from the amino group, amino acids are condensed sequentially from the C-terminus to the N-terminus (from right to left).

[0760] Step 1: Solid-phase synthesis

[0761] Weigh Fmoc-Linker MBHA Resin (S = 0.32 mmol / g) and place it in a glass reaction column. Add DCM and allow to swell for 30 minutes. Remove the DCM under reduced pressure. Add a 20% piperidine / DMF solution and react for 20 minutes to remove the Fmoc protecting group. Remove the solution under reduced pressure and wash five times with DMF. Samples were collected for color development and analysis to obtain a solid-phase resin with amino groups attached.

[0762] Weigh Fmoc-Gly-OH and add it to the resin. Dissolve it in DMF and add DIEA and TBTU. Stir for 60 minutes, remove the solution under reduced pressure, and wash five times with DMF. Take a sample and develop color for detection to obtain a solid-phase resin with GLY NH2 attached.

[0763] Repeat this process to sequentially couple His, Lys, Ahp (from the raw material Fmoc-7-Ahp-OH), and Biotin, and finally obtain a solid phase resin connected with BIO P06 LYS HIS GLY NH2, i.e., a peptide resin.

[0764] Then, the resin was washed three times with DMF, DCM, and methanol in sequence and dried to constant weight.

[0765] Step 2: Peptide resin cleavage

[0766] Preparation of cleavage reagent: Calculate the amount of cleavage reagent based on a volume of 10 mL ± 2 mL of cleavage reagent (TFA:H₂O:TIS = 95:2.5:2.5, volume ratio) per 1 g of peptide resin. Sequentially add the required cleavage reagents, H₂O, TFA, and TIS, to the cleavage reaction vial. Keep the cleavage reagent temperature between 0 and 10°C. Stir the cleavage reagent into the peptide resin. Once the system temperature stabilizes, maintain the reaction at 25 to 30°C with stirring for 2.5 hours.

[0767] The lysate was filtered out and precipitated with 5 times the volume of icy ether. The precipitate was filtered out and washed three times with 3 times the volume of icy ether, and then dried under reduced pressure at room temperature to obtain a crude solid product.

[0768] Step 3: Freeze-drying and purification

[0769] The crude product was ground finely, purified water was prepared, and the ground product was slowly added to the mixture while stirring. Simultaneously, acetonitrile aqueous solution was added dropwise. After the crude product was completely added and dissolved, it was filtered through a 0.45μm microporous filter membrane. The crude product was purified using a C-18 preparative column with mobile phase A: 0.1% TFA aqueous solution and mobile phase B: 0.1% TFA acetonitrile solution. Separation and purification were performed at room temperature using an appropriate gradient. The target product was collected, analyzed, tested, and classified. The purity requirement was ≥95%. Unqualified target products were collected and separated and purified again using an appropriate gradient. The qualified main peak was freeze-dried under reduced pressure to obtain a powdered purified polypeptide.

[0770] Those skilled in the art can refer to the above synthesis steps to prepare other linear peptide compounds of the present application.

[0771] 2. Identification of linear peptide compounds

[0772] Weigh the purified peptide prepared above and dissolve it in a mixture of water and acetonitrile until the solution is clear. Filter and load the sample. HPLC conditions: C18 column, 4.6 μm × 250 mm; mobile phase A: 0.1% TFA in acetonitrile, mobile phase B: 0.1% TFA in water; gradient: 25% A, 75% B (0.01 min) → 50% A, 50% B (25.01 min) → 100% A (25.01 min) → stop (30 min); detection wavelength: 220 nm; flow rate: 1.0 ml / min; column temperature: 25°C; injection volume: 10 μL.

[0773] The mass spectrometer detector was Agilent-6125B, using an electrospray ionization source (ESI) and positive ion scanning; the mass spectrometer voltage was +4.5 kV; the detector was 1.5 kV; the nebulizer flow rate was 1.5 L / min; the CDL was -20.0 v; the CDL temperature was 250 ° C; the heating module temperature was 200 ° C; the mobile phase was 50% water / 50% acetonitrile; and the flow rate was 0.2 mL / min.

[0774] The mass spectrometry data of some exemplary linear peptide compounds are shown in Table 1 below.

[0775] Table 1: Mass spectrometry data of some exemplary linear peptide compounds

[0776] As shown in Table 1, the preparation method of the present invention can successfully obtain the expected linear peptide compound.

[0777] Example 2: Biological activity test of linear peptide compounds

[0778] 1. Test method

[0779] A. Fibroblast toxicity test

[0780] Test materials: human fibroblasts (Guangdong Boxi Biotechnology Co., Ltd., batch number Fb20081902), DMEM culture medium (Gibco, 23042301, expiration date 230522), PBS (Solarbio, P1010), MTT (Sigma, M5655), DMSO (Sigma, D4540-1L), CO2 incubator (Thermo, 150I), clean bench (Sujing Antai, SW-CJ-1F), inverted microscope (Olympus, CKX53).

[0781] Test method:

[0782] 1) Cell seeding: After thawing the cells, when the plating rate reaches about 60%, seed the cells into a 96-well plate and incubate in an incubator (37° C., 5% CO 2 ) overnight.

[0783] 2) Experimental Grouping: The experiment was divided into a zero adjustment group, a solvent control group, a positive control group, and a sample group. In the sample group, each sample was set up with 7 concentration gradients, and 3 replicate wells were set up under each concentration gradient.

[0784] 3) Solution preparation: Prepare sample working solutions of different concentrations according to the test concentrations of 0.0781, 0.1563, 0.3125, 0.625, 1.25, 2.5, and 5 μM.

[0785] 4) Dosing: Dosing was performed when the cell plating rate in the 96-well plate reached 50% to 60%. For the solvent control group, 200 μL of culture medium was added to each well; for the positive control group, 200 μL of culture medium containing 10% DMSO was added to each well; for the sample group, 200 μL of culture medium containing the corresponding sample concentration was added to each well; for the zero-adjustment group, no cells were seeded, and only 200 μL of cell culture medium was added. After dosing, the 96-well plate was placed in an incubator (37°C, 5% CO2) and incubated for 24 hours.

[0786] 5) Detection: After incubating the cells for 24 h, discard the supernatant and add MTT working solution (0.5 mg / mL). Incubate at 37°C in the dark for 4 h. After incubation, discard the supernatant and add 150 μL DMSO to each well. Read the OD value at 490 nm.

[0787] 6) Calculation of relative cell viability: Calculate according to the following formula

[0788] The test results of some exemplary linear peptide compounds are shown in Table 2.

[0789] Table 2: Test results of exemplary linear peptide compounds

[0790] As shown in Table 2, in the fibroblast toxicity test, all linear peptide compounds showed no obvious cytotoxicity within the concentration range of 5 μM, and have good application prospects in medicine and cosmetics.

[0791] B. Fibroblast Collagen I (Type I collagen) lifting effect, fibroblast HA (hyaluronic acid lifting effect, fibroblast elastin (ELN) lifting effect

[0792] Test materials: Human fibroblasts (Guangdong Boxi Biotechnology Co., Ltd., batch number Fb20081902), DMEM medium (Gibco, 23042301, expiration date 230522), PBS (Solarbio, P1010), TGF-β1 (Peprotech, 230504), Collagen I ELISA kit (Cusabio, B21025824), Elastin ELISA kit (Abcam, GR3446070-2), HA ELISA kit (RD, P325066). CO2 incubator (Thermo, 150I), clean bench (Sujing Antai, SW-CJ-1F), and microplate reader (BioTek, Epoch).

[0793] Test method:

[0794] 1) Inoculation: After thawing cells, when the plating rate reaches about 60%, inoculate the cells into 6-well plates and incubate in an incubator (37° C., 5% CO 2 ) overnight.

[0795] 2) Solution preparation: linear peptide compound in the sample group, PC2 (Biotinoyl-GHK, ) and PC3 The concentration of each test substance was 1 μM, and the working solution of the test substance was prepared.

[0796] 3) Drug administration: When the cell plating rate in the 6-well plate reaches 40% to 60%, drug administration is performed, with a dosage of 2 mL per well. Each group has 3 replicate wells and incubated in an incubator (37° C., 5% CO 2 ) for 24 h.

[0797] 4) ELISA test: ELISA test was performed according to the instructions of the ELISA kit. The test indicators were the fibroblast Collagen I enhancement effect, the fibroblast HA enhancement effect, and the fibroblast elastin enhancement effect.

[0798] The activity test data of some exemplary linear peptide compounds are shown in Tables 3A, 3B, and 3C below.

[0799] Table 3A: Data on the fibroblast Collagen I enhancement effect of some exemplary linear peptide compounds

[0800] As shown in Table 3A, compared with BC, the exemplary linear peptide compounds of the present invention, such as the linear peptide compounds represented by SEQ ID NOs: 77, 224, 242, 265, 286, 294, 296, 337, 338, 349, 358, 373, 397, 403, 406, 415, 417, 419, 424, 76, 234, 6, 23, and 256, significantly increased the type I collagen (Collagen I) content, indicating that the linear peptide compounds of the present invention can achieve anti-wrinkle efficacy by increasing the content of Collagen I.

[0801] Table 3B: Data on the fibroblast HA enhancement effect of some exemplary linear peptide compounds

[0802] As shown in Table 3B, compared with BC, the hyaluronic acid (HA) content of exemplary linear peptide compounds of the present invention, such as the linear peptide compounds represented by SEQ ID NOs: 21, 77, 23, 76, 286, 294, 336, 337, 338, 358, 397, 415, 234, 256, 296, 349, 373, 403, 406, and 417, was significantly increased, indicating that the linear peptide compounds of the present invention can achieve a firming effect by increasing the HA content.

[0803] Table 3C: Data on the fibroblast elastin-enhancing effects of some exemplary linear peptide compounds

[0804] As shown in Table 3C, compared with BC, the elastin content of the exemplary linear peptide compounds of the present invention represented by SEQ ID NOs: 21, 77, 23, 76, 286, 294, 336, 337, 338, 358, 397, 415, 234, 6, 224, 242, 256, 265, 296, 349, 373, 403, 406, 417, 419, and 424 was significantly increased, indicating that the linear peptide compounds of the present invention can achieve a firming effect by increasing the elastin content.

[0805] In addition, as shown in Tables 3A, 3B, and 3C, compared to BC, the exemplary linear peptide compounds of the present invention, such as the linear compounds represented by SEQ ID NOs: 77, 76, 286, 294, 234, 23, 256, 296, 337, 338, 349, 358, 373, 397, 403, 406, 415, and 417, significantly increased type I collagen (Collagen I) content, hyaluronic acid (HA) content, and elastin content. This indicates that the linear peptide compounds of the present invention can achieve firming and anti-wrinkle effects by increasing the content of Collagen I, HA, and elastin, and have excellent medical and cosmetic effects.

Claims

1. A linear peptide compound represented by formula O or a stereoisomer thereof, R 1 -(AA 1 ) n1 -(AA 2 ) n2 -(L 1 ) n3 -(AA 3 ) n4 -AA a -AA b -AA c -(L 2 ) n5 -(AA 4 ) n6 -(AA 5 ) n7 -(AA a -AA b -AA c ) m -R 2 Formula O in: n1, n2, n3, n4, n5, n6, n7 are each independently selected from 0 and 1; m is selected from 0 and 1; and the following two conditions are satisfied: 1) When n1 and n7 are both 0, n3 and n5 are not both 0; 2) When n3 and n5 are both 0, n1 and n7 are not both 0; AA a An amino acid residue selected from the group consisting of GLY, LYS, DLYS, LYO, LHY, LHI, LPY; Preferably, AA a An amino acid residue selected from the group consisting of GLY, LYS, DLYS, LYO, LHY; More preferably, AA a are the following amino acid residues: GLY, LYS; AA b Selected from the following amino acid residues: HIS, DHIS; Preferably, AA b are the following amino acid residues: HIS; AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY, GLY; Preferably, AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, GLY; More preferably, AA c An amino acid residue selected from the group consisting of LYS, LYO, LHY, GLY; Most preferably, AA c are the following amino acid residues: LYS, GLY; Among them, AA a When it is the following amino acid residues: GLY, AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY, and AA a When selected from the following amino acid residues: LYS, DLYS, LYO, LHY, LHI, LPY, AA c is the following amino acid residue: GLY; Preferably, AA a -AA b -AA c selected as a whole from the following peptide residues: GLY HIS LYS, LYS HIS GLY, GLY DHIS DLYS, GLY HIS LYO, GLY HIS LHY, GLY HIS LHI, GLY HIS LPY; AA 1 Selected from the following amino acid residues: AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, D-M3L; Preferably, AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30; AA 2 Selected from the following amino acid residues: M3L, 2MR, ALA, GLY; AA 3 are the following amino acid residues: M3L; AA 4 Selected from the following amino acid residues: ALA, GLY, PRO; Preferably, AA 4 Selected from the following amino acid residues: ALA, GLY; AA 5 Selected from the following amino acid residues: M3L, 4PH, ZCL, A30, DOQ, EXL, OUO, D-4PH, D-ZCL, D-A30; Preferably, AA 5 selected from the following amino acid residues: M3L, 4PH, ZCL, A30; R 1 Selected from ACE, PAL, BIO, PEG, VIC; Preferably, R 1 Selected from ACE, PAL, BIO; More preferably, R 1 For ACE; R 2 Selected from NME, -OH, -NH2; Preferably, R 2 For NME; L 1 Selected from P01, P02, P03, P04, P05, P06, P07, P08, P09, P10, P11, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25, P26, P27, P28, P29, P30; Preferably, L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29; More preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29; Most preferably, L 1 Selected from P23, P21, P06, P20, P25; L 2 Selected from P01, P02, P03, P04, P05, P06, P07, P08, P09, P10, P11, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25, P26, P27, P28, P29, P30; Preferably, L 2 Selected from P05, P06, P07, P08, P19, P20, P21, P22, P23, P24, P25, P29; More preferably, L 2 Selected from P05, P06, P07, P08, P19, P20, P21, P22, P23, P24, P25; Wherein, in the linear peptide compound represented by Formula O, from left to right is N-terminus to C-terminus; Among them, the meanings of P01, P02, P03, P04, P05, P06, P07, P08, P09, P10, P11, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25, P26, P27, P28, P29, P30, ACE, PAL, BIO, PEG, VIC, NME, GLY, HIS, DHIS, LYS, DLYS, LYO, LHY, LHI, LPY, AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, D0Q, EXL, 0UO, D-4PH, D-ZCL, D-A30, D-M3L, ALA, and PRO are as shown in Table E.

2. The linear peptide compound or a stereoisomer thereof according to claim 1, wherein The linear peptide compound has a structure shown in Formula I, R 1 -AA a -AA b -AA c -L 2 -AA a -AA b -AA c -R 2 Formula I in: AA a is the following amino acid residue: GLY; AA b Selected from the following amino acid residues: HIS, DHIS; Preferably, AA b are the following amino acid residues: HIS; AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY; Preferably, AA c are the following amino acid residues: LYS; Preferably, AA a -AA b -AA c As a whole, the following peptide residues: GLY HIS LYS; R 1 Selected from ACE, PAL, BIO; Preferably, R 1 For ACE; R 2 Selected from NME, -OH, -NH2; Preferably, R 2 For NME; L 2 Selected from P01, P02, P03, P04, P05, P06, P07, P08, P09, P10, P11, P12, P13, P14, P15, P16, P17, P18, P19, P20, P21, P22, P23, P24, P25, P26, P27, P28, P29, P30; Preferably, L 2 Selected from P05, P06, P07, P08, P19, P20, P21, P22, P23, P24, P25, P29; More preferably, L 2 Selected from P05, P06, P07, P08, P19, P20, P21, P22, P23, P24, P25.

3. The linear peptide compound or a stereoisomer thereof according to claim 1, wherein The linear peptide compound has a structure shown in Formula II, R 1 -(AA 1 ) n1 -(AA 2 ) n2 -L 1 -(AA 3 ) n4 -AA a -AA b -AA c -(AA 4 ) n6 -(AA 5 ) n7 -R 2 Formula II in: n1, n2, n4, n6, n7 are each independently selected from 0 and 1; Preferably, n1 is selected from 0 and 1, and n2, n4, n6 and n7 are all 0; Or preferably, n1, n2, n4, n6, and n7 are all 0; AA a An amino acid residue selected from the group consisting of GLY, LYS, DLYS, LYO, LHY; Preferably, AA a selected from the following amino acid residues: GLY, LYS; AA b Selected from the following amino acid residues: HIS, DHIS; Preferably, AA b are the following amino acid residues: HIS; AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, GLY; Preferably, AA c An amino acid residue selected from the group consisting of LYS, LYO, LHY, GLY; Preferably, AA c selected from the following amino acid residues: LYS, GLY; Among them, AA a When it is the following amino acid residues: GLY, AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, and AA a When selected from the following amino acid residues: LYS, DLYS, LYO, LHY, AA c is the following amino acid residue: GLY; Preferably, AA a -AA b -AA c As a whole, selected from the following peptide residues: GLY HIS LYS, LYS HIS GLY, GLY DHIS DLYS, GLY HIS LYO, GLY HIS LHY; AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30; Preferably, AA 1 are the following amino acid residues: M3L; AA 2 are the following amino acid residues: M3L; AA 3 are the following amino acid residues: M3L; AA 4 Selected from the following amino acid residues: GLY, ALA; AA 5 are the following amino acid residues: 4PH; R 1 Selected from ACE, PAL, BIO; Preferably, R 1 For ACE; R 2 Selected from NME, -OH, -NH2; Preferably, R 2 For NME; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29; Preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29; More preferably, L 1 Selected from P23, P21, P06, P20, P25.

4. The linear peptide compound or a stereoisomer thereof according to claim 3, wherein The linear peptide compound has a structure shown in formula II-1, R 1 -(AA 1 ) n1 -(AA 2 ) n2 -L 1 -(AA 3 ) n4 -AA a1 -AA b1 -AA c1 -(AA 4 ) n6 -(AA 5 ) n7 -R 2 Formula II-1 in: n1, n2, n4, n6, n7 are each independently selected from 0 and 1; Preferably, n1 is selected from 0 and 1, and n2, n4, n6 and n7 are all 0; AA a1 is the following amino acid residue: GLY; AA b1 Selected from the following amino acid residues: HIS, DHIS; Preferably, AA b1 are the following amino acid residues: HIS; AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY; Preferably, AA c1 are the following amino acid residues: LYS, LYO, LHY; Preferably, AA c1 are the following amino acid residues: LYS; Preferably, AA a1 -AA b1 -AA c1 As a whole, selected from the following peptide residues: GLY HIS LYS, GLY DHIS DLYS, GLY HIS LYO, GLY HIS LHY; AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30; Preferably, AA 1 are the following amino acid residues: M3L; AA 2 are the following amino acid residues: M3L; AA 3 are the following amino acid residues: M3L; AA 4 Selected from the following amino acid residues: GLY, ALA; AA 5 are the following amino acid residues: 4PH; R 1 Selected from ACE, PAL, BIO; Preferably, R 1 For ACE; R 2 Selected from NME, -OH, -NH2; Preferably, R 2 For NME; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29; Preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29; More preferably, L 1 Selected from P23, P21, P06, P20, P25.

5. The linear peptide compound or a stereoisomer thereof according to claim 3, wherein: The linear peptide compound has a structure shown in formula II-2, R 1 -(AA 1 ) n1 -L 1 -AA a2 -AA b2 -AA c2 -R 2 Formula II-2 in: n1 is selected from 0 and 1; Preferably, n1 is 0; AA a2 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY; Preferably, AA a2 are the following amino acid residues: LYS; AA b2 Selected from the following amino acid residues: HIS, DHIS; Preferably, AA b2 are the following amino acid residues: HIS; AA c2 is the following amino acid residue: GLY; Preferably, AA a2 -AA b2 -AA c2 As a whole, the following peptide residues: LYS HIS GLY; AA 1 are the following amino acid residues: M3L; R 1 Selected from ACE, PAL, BIO; R 2 Selected from NME, -OH, -NH2; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P25, P29; Preferably, L 1 Selected from P23, P21, P06, P20, P25, P29; More preferably, L 1 Selected from P23, P21, P06, P20, P25.

6. The linear peptide compound or a stereoisomer thereof according to claim 1, wherein The linear peptide compound has a structure shown in Formula III, R 1 -AA 1 -(AA 2 ) n2 -AA a -AA b -AA c -(AA 4 ) n6 -AA 5 -R 2 Formula III in: n2 and n6 are each independently selected from 0 and 1; Preferably, n2 is 0, and n6 is selected from 0 and 1; Or preferably, n2 is selected from 0, 1, and n6 is 0; AA a An amino acid residue selected from the group consisting of GLY, LYS, DLYS, LYO, LHY; Preferably, AA a selected from the following amino acid residues: GLY, LYS; AA b Selected from the following amino acid residues: HIS, DHIS; Preferably, AA b are the following amino acid residues: HIS; AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY, GLY; Preferably, AA c An amino acid residue selected from the group consisting of LYS, LYO, LHY, GLY; More preferably, AA c selected from the following amino acid residues: LYS, GLY; Among them, AA a When it is the following amino acid residues: GLY, AA c An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY, and AA a When selected from the following amino acid residues: LYS, DLYS, LYO, LHY, AA c is the following amino acid residue: GLY; Preferably, AA a -AA b -AA c selected as a whole from the following peptide residues: GLY HIS LYS, LYS HIS GLY, GLY DHIS DLYS, GLY HIS LYO, GLY HIS LHI, GLY HIS LHY, GLY HIS LPY; R 1 Selected from ACE, PAL, BIO, PEG, VIC; Preferably, R 1 Selected from ACE, PAL, BIO; R 2 Selected from NME, -OH, -NH2; AA 1 Selected from the following amino acid residues: AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, D-M3L; Preferably, AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30; More preferably, AA 1 Selected from the following amino acid residues: 4PH, ZCL, A30; More preferably, AA 1 are the following amino acid residues: M3L; AA 2 Selected from the following amino acid residues: M3L, 2MR, ALA, GLY; Preferably, AA 2 Selected from the following amino acid residues: M3L, 2MR; Preferably, AA 2 Selected from the following amino acid residues: ALA, GLY; AA 4 Selected from the following amino acid residues: ALA, GLY, PRO; Preferably, AA 4 Selected from the following amino acid residues: ALA, GLY; AA 5 Selected from the following amino acid residues: M3L, 4PH, ZCL, A30, DOQ, EXL, OUO, D-4PH, D-ZCL, D-A30; Preferably, AA 5 Selected from the following amino acid residues: M3L, 4PH, ZCL, A30; More preferably, AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30; More preferably, AA 5 is the following amino acid residue: M3L.

7. The linear peptide compound or a stereoisomer thereof according to claim 6, wherein The linear peptide compound has a structure shown in formula III-1, R 1 -AA 1 -(AA 2 ) n2 -AA a1 -AA b1 -AA c1 -(AA 4 ) n6 -AA 5 -R 2 Formula III-1 in: n2 and n6 are each independently selected from 0 and 1; Preferably, n2 is 0, and n6 is selected from 0 and 1; AA a1 is the following amino acid residue: GLY; AA b1 Selected from the following amino acid residues: HIS, DHIS; Preferably, AA b1 are the following amino acid residues: HIS; AA c1 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY, LHI, LPY; Preferably, AA c1 An amino acid residue selected from the group consisting of: LYS, LYO, LHY; More preferably, AA c1 are the following amino acid residues: LYS; Preferably, AA a1 -AA b1 -AA c1 selected as a whole from the following peptide residues: GLY HIS LYS, GLY DHIS DLYS, GLY HIS LYO, GLY HIS LHI, GLY HIS LHY, GLY HIS LPY; R 1 Selected from ACE, PAL, BIO, PEG, VIC; Preferably, R 1 Selected from ACE, PAL, BIO; R 2 Selected from NME, -OH, -NH2; AA 1 Selected from the following amino acid residues: AGM, NMM, 2MR, MLZ, MLY, M3L, 4PH, ZCL, A30, D-M3L; Preferably, AA 1 Selected from the following amino acid residues: M3L, 4PH, ZCL, A30; More preferably, AA 1 are the following amino acid residues: M3L; AA 2 Selected from the following amino acid residues: M3L, 2MR; AA 4 Selected from the following amino acid residues: ALA, GLY, PRO; Preferably, AA 4 Selected from the following amino acid residues: ALA, GLY; AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30, DOQ, EXL, OUO, D-4PH, D-ZCL, D-A30; Preferably, AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30.

8. The linear peptide compound or a stereoisomer thereof according to claim 6, wherein The linear peptide compound has a structure shown in formula III-2, R 1 -AA 1 -(AA 2 ) n2 -AA a2 -AA b2 -AA c2 -AA 5 -R 2 Formula III-2 in: n2 is selected from 0 and 1; AA a2 An amino acid residue selected from the group consisting of LYS, DLYS, LYO, LHY; Preferably, AA a2 are the following amino acid residues: LYS; AA b2 Selected from the following amino acid residues: HIS, DHIS; Preferably, AA b2 are the following amino acid residues: HIS; AA c2 is the following amino acid residue: GLY; Preferably, AA a2 -AA b2 -AA c2 As a whole, the following peptide residues: LYS HIS GLY; R 1 Selected from ACE, PAL, BIO, PEG, VIC; Preferably, R 1 Selected from ACE, PAL, BIO; Preferably, R 1 For ACE; R 2 Selected from NME, -OH, -NH2; Preferably, R 2 For NME; AA 1 selected from the following amino acid residues: M3L, 4PH, ZCL, A30; Preferably, AA 1 Selected from the following amino acid residues: 4PH, ZCL, A30; AA 2 Selected from the following amino acid residues: ALA, GLY; AA 5 selected from the following amino acid residues: M3L, 4PH, ZCL, A30; Preferably, AA 5 is the following amino acid residue: M3L.

9. The linear peptide compound or a stereoisomer thereof according to any one of claims 1 to 8, wherein: The linear peptide compound has a structure shown in Formula IV, R 1 -(AA 1 ) n1 -(L 1 ) n3 -AA a -AA b -AA c -(AA 5 ) n7 -R 2 Formula IV in: n1, n3, n7 are each independently selected from 0 and 1, and are not 0 at the same time; Preferably, n1 and n7 are selected from 0, and n3 is selected from 1; or n1 and n7 are selected from 1; n3 is selected from 0; or n1 and n3 are selected from 1, and n7 is selected from 0; AA a -AA b -AA c As a whole, selected from the following peptide residues: LYS HIS GLY, GLY HIS LYS, GLY HIS LYO, GLY HIS LHY; Preferred AA a -AA b -AA c As a whole, selected from the following peptide residues: LYS HIS GLY, GLY HIS LYS, GLY HIS LYO; AA 1 Selected from the following amino acid residues: M3L, AGM, NMM, 2MR, MLZ, MLY, 4PH, ZCL, A30, D-M3L; Preferably, AA 1 Selected from the following amino acid residues: M3L, 4PH, ZCL, A30; Preferably, AA 1 Selected from the following amino acid residues: M3L, 4PH; Preferably, AA 1 Selected from the following amino acid residues: M3L; AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30, DOQ, EXL, OUO, M3L, D-4PH, D-ZCL, D-A30; Preferably, AA 5 Selected from the following amino acid residues: 4PH, ZCL, A30, M3L; Preferably, AA 5 Selected from the following amino acid residues: 4PH, A30, M3L; Preferably, AA 5 Selected from the following amino acid residues: 4PH; Preferably, AA 5 selected from the following amino acid residues: A30; L 1 Selected from P15, P10, P13, P23, P11, P21, P06, P12, P14, P20, P05, P07, P08, P19, P22, P24, P25, P29; Preferably, L 1 Selected from P23, P21, P06, P20, P05, P07, P08, P19, P22, P24, P25, P29; Preferably, L 1 Selected from P21, P06, P23, P25, P20; Preferably, L 1 Selected from P21, P06, P25, P23; R 1 Selected from ACE, PAL, BIO, PEG, VIC; Preferably, R 1 Selected from ACE, PAL, BIO; Preferably, R 1 Selected from ACE, PAL; More preferably, R 1 Selected from ACE; R 2 Selected from NME, -OH, -NH2; Preferably, R 2 Selected from NME, -OH; More preferably, R 2 Selected from NME.

10. The compound or stereoisomer thereof according to any one of claims 1 to 9, wherein The structures of the linear peptide compounds are shown in Table A, Table A-1, Table A-2, Table B-1, Table B-2, Table B-3, Table C-1, Table C-2, Table D, Table D-1 and / or Table D-2.

11. A pharmaceutical composition comprising the linear peptide compound or a stereoisomer thereof according to any one of claims 1 to 10; Optionally, at least one carrier and / or excipient is also included.

12. A cosmetic composition comprising the linear peptide compound or a stereoisomer thereof according to any one of claims 1 to 10; Optionally, further comprising a functional substance; Preferably, the functional substance is selected from one or more of skin conditioners, antioxidants, surfactants, moisturizers, preservatives, chelating agents, and fragrances.

13. Use of the linear peptide compound or its stereoisomer according to any one of claims 1 to 10 or the pharmaceutical composition according to claim 11 in the preparation of a drug, wherein the drug is used for one or more selected from the following (1) to (7): (1) Delay skin aging; (2) Reduce skin damage; (3) Accelerate skin wound healing; (4) Reduce hyperpigmentation; (5) Stimulate hair growth; (6) Improve the success rate of hair transplantation; (7) Prevent hair loss.

14. Use of the linear peptide compound or stereoisomer thereof according to any one of claims 1 to 10 or the cosmetic composition according to claim 12 for one or more selected from the following (1) to (17): (1) Anti-aging of the skin; (2) Anti-wrinkle and reduce fine lines; (3) Improve the mechanical properties of the skin: firmness, skin tone, elasticity and / or flexibility; (4) Improve skin density; (5) Increase skin volume; (6) Counteract the appearance of traction marks; (7) Reduce skin damage; (8) Accelerate skin wound healing; (9) Anti-plaque; (10) Improve skin homogeneity and / or radiance; (11) Reduce skin pigmentation; (12) Moisturizing; (13) Stimulate hair growth; (14) Improve the success rate of hair transplantation; (15) Prevent hair loss; (16) Local beauty treatment of eyelashes; (17) Increase hair width, density and / or length.

Images